In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its ...
The Middle East crisis led to a broad selloff in Russell equity segments in March, halting the year-long rally.
The latest type 2 diabetes (T2D) management guidance from the American Association of Clinical Endocrinology (AACE) covers ...
Stoner songs that blazed their way up the chart.
The 13-day win streaks in the Nasdaq Composite and Nasdaq 100 are about to end — unless both indexes climb into the green by ...
Machine learning can sound pretty complicated, right? Like something only super-smart tech people get. But honestly, it’s ...
Joining the ranks and reaching a $1 trillion valuation is a milestone. But staying there is also a challenge. Eli Lilly (NYSE ...
Nektar Therapeutics (NASDAQ:NKTR) shares rose 20% after the company reported positive 52-week data from its Phase 2b REZOLVE-AA study evaluating rezpegaldesleukin in patients with ...
Merck (NYSE:MRK) announced on Monday that the U.S. Food and Drug Administration granted priority review for two supplemental Biologics License Applications for KE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results